15 companies

Inventiva

Market Cap: €773.8m

A clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally.

IVA

€3.42

7D

11.4%

1Y

30.3%

Valneva

Market Cap: €425.8m

A specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.

VLA

€2.34

7D

4.7%

1Y

-5.8%

Cellectis

Market Cap: €206.9m

A clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications.

ALCLS

€2.85

7D

16.4%

1Y

104.0%

Innate Pharma

Market Cap: €150.1m

Operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.

IPH

€1.66

7D

5.6%

1Y

9.0%

Sensorion

Market Cap: €133.8m

A biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France.

ALSEN

€0.26

7D

10.9%

1Y

-27.0%

Adocia

Market Cap: €87.1m

A clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity.

ADOC

€4.45

7D

5.3%

1Y

17.8%

OSE Immunotherapeutics

Market Cap: €73.9m

A clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally.

OSE

€3.73

7D

18.7%

1Y

-27.1%

ABIONYX Pharma

Market Cap: €73.4m

A biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States.

ABNX

€2.08

7D

2.0%

1Y

72.2%

AB Science

Market Cap: €58.7m

A clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France.

AB

€0.77

7D

-11.6%

1Y

-52.5%

MaaT Pharma

Market Cap: €49.7m

A late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival.

MAAT

€2.88

7D

13.8%

1Y

-45.0%

THX Pharma Société Anonyme

Market Cap: €45.7m

A biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.

ALTHX

€3.68

7D

16.8%

1Y

211.9%

Nicox

Market Cap: €33.6m

Operates as an ophthalmology company in France and internationally.

ALCOX

€0.38

7D

3.5%

1Y

71.6%

Valbiotis

Market Cap: €19.5m

Engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia.

ALVAL

€0.85

7D

14.1%

1Y

-1.4%

GenSight Biologics

Market Cap: €18.8m

A clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system.

SIGHT

€0.083

7D

3.4%

1Y

-45.2%

Advicenne

Market Cap: €18.1m

A specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally.

ALDVI

€1.40

7D

30.8%

1Y

4.2%